Login to Your Account



Prostate Drug Just in Time?

$650M Aragon Buyout Brings J&J's Replacement for Zytiga

By Randy Osborne
Staff Writer

Monday, June 17, 2013
deals_and_ma.jpg

Johnson & Johnson's (J&J) planned takeover of Aragon Pharmaceuticals Inc. for $650 million in cash and $350 million more in potential milestone payments brings aboard the Phase III-ready ARN-509 for castration-resistant prostate cancer (CRPC) behind the pharma firm's approved androgen inhibitor Zytiga (abiraterone acetate) for the same indication.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription